Drug Trial Radar · NCT07539311
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Sep 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Apr 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study will be conducted in different countries around the world with up to about 160 participants. The purpose of this study is to evaluate how well Rina-S works against GI cancers. The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective. The duration of the study will be different for every participant, but an average study duration of 22 months is expected for participants. This will include a treatment period (expected to last an average of 12 months), plus data collection periods before and after treatment. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of an individual cycle is 21 days). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.
Conditions
- Gastrointestinal Cancers
Interventions
Rina-SBiological
Intravenous (IV) administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 22 months
Locations
28 sites in 11 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCLA Hematology/Oncology, Santa Monica
Santa Monica, California · Recruiting
University of Colorado Hospitak Anschutz
Aurora, Colorado · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Greco-Hainsworth Center for Research
Nashville, Tennessee · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
Cancer Research SA Pty Ltd
Adelaide, Australia · Recruiting
GenesisCare St Leonards
Saint Leonards, New South Wales, Australia · Recruiting
St John of God Subiaco Hospital
Subiaco, Western Australia, Australia · Recruiting
Cliniques Universitaires Saint-Luc | Cliniques Universitaires Saint-Luc|Head and Neck tumors, Route 407 | Cliniques Universitaires Saint-Luc|Hematology
Brussels, Belgium · Recruiting
Centre Hospitalier de l'Ardenne|Service Oncologie
Libramont, Belgium · Recruiting
Hôpital Saint-Antoine Onco Med
Paris, France · Recruiting
CHU Brest Cavale Blanche
Brest, Brittany (Bretagne), France · Recruiting
Institut Régional du Cancer de Montpellier
Montpellier, Herault, France · Recruiting
Hôpital Européen Georges Pompidou
Paris, Paris, France · Recruiting
Centre Leon Berard
Lyon, Rhone, France · Recruiting
Asklepios Klinik Altona
Hamburg, Free and Hanseatic City of Hamburg, Germany · Recruiting
National Cancer Center Hospital East
Kashiwa, Chiba, Japan · Recruiting
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan · Recruiting
The University of Osaka Hospital
Suita, Osaka, Japan · Recruiting
Cancer Institute Hospital of JFCR
Kōtoku, Tokyo-To, Japan · Recruiting
Amsterdam UMC, Locatie VUMC|Hematology
Amsterdam, Netherlands · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Madrid, Spain · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
University College London Hospitals
London, Greater London, United Kingdom · Recruiting
Hammersmith Hospital
London, Greater London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.